These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24679056)

  • 1. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
    Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
    Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice.
    Dhadwar SS; Kiernan J; Wen J; Hortelano G
    J Thromb Haemost; 2010 Dec; 8(12):2743-50. PubMed ID: 20961391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
    Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
    Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.
    Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T
    Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
    Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
    Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.
    Bowman K; Sarkar R; Raut S; Leong KW
    J Control Release; 2008 Dec; 132(3):252-9. PubMed ID: 18634839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice.
    Suwanmanee T; Hu G; Gui T; Bartholomae CC; Kutschera I; von Kalle C; Schmidt M; Monahan PE; Kafri T
    Mol Ther; 2014 Mar; 22(3):567-574. PubMed ID: 23941813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
    Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW
    Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
    Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson JM; Collen D; Chuah MK
    J Thromb Haemost; 2007 Jan; 5(1):16-24. PubMed ID: 17002653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
    Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
    Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.
    Chen Y; Schroeder JA; Kuether EL; Zhang G; Shi Q
    Mol Ther; 2014 Jan; 22(1):169-77. PubMed ID: 24042561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
    Sun J; Hakobyan N; Valentino LA; Feldman BL; Samulski RJ; Monahan PE
    Blood; 2008 Dec; 112(12):4532-41. PubMed ID: 18716130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B.
    Brunetti-Pierri N; Grove NC; Zuo Y; Edwards R; Palmer D; Cerullo V; Teruya J; Ng P
    Hum Gene Ther; 2009 May; 20(5):479-85. PubMed ID: 19196177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.